Several PD-(L)1 inhibitors for advanced gastric cancer, including pembrolizumab, nivolumab, and sintilimab, have been approved in first-line or third-line settings in Europe, the USA, and Asia (Table 2). The gene discussed is CD274; the disease is gastric cancer.